These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36669104)

  • 1. Inhibition of
    Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
    Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
    Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Wang P; Wu CX; Li Y; Shen N
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
    Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
    Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
    J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
    Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
    Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
    Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
    World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model.
    Ma Y; Cai H; Smith J; Chu CH; Mercer SE; Boehm S; Mcdonald I; Zinker B; Cheng D
    J Lipid Res; 2024 Mar; 65(3):100514. PubMed ID: 38309418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine HSD17β13 does not control liver steatosis and modestly impacts fibrosis in a sex- and diet-specific manner.
    Crane JD; Barrandon O; Faherty B; Gorgoglione M; Crowley C; Morin J; Ross TT; Shimkonis J; Li D; Hirenallur-Shanthappa D; Boucher M; Ahn Y; Clasquin MF
    J Lipid Res; 2024 Oct; 65(10):100634. PubMed ID: 39182609
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
    Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
    Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.
    Amangurbanova M; Huang DQ; Loomba R
    Aliment Pharmacol Ther; 2023 Jan; 57(1):37-51. PubMed ID: 36349732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
    Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
    BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding 17-Beta-hydroxysteroid Dehydrogenase 13: A Multifaceted Perspective on Its Role in Hepatic Steatosis and Associated Disorders.
    Demirtas CO; Yilmaz Y
    J Clin Transl Hepatol; 2024 Oct; 12(10):857-864. PubMed ID: 39440221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.
    Luukkonen PK; Tukiainen T; Juuti A; Sammalkorpi H; Haridas PAN; Niemelä O; Arola J; Orho-Melander M; Hakkarainen A; Kovanen PT; Dwivedi O; Groop L; Hodson L; Gastaldelli A; Hyötyläinen T; Orešič M; Yki-Järvinen H
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.
    Wang M; Li J; Li H; Dong B; Jiang J; Liu N; Tan J; Wang X; Lei L; Li H; Sun H; Tang M; Wang H; Yan H; Li Y; Jiang J; Peng Z
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.
    Liu WY; Eslam M; Zheng KI; Ma HL; Rios RS; Lv MZ; Li G; Tang LJ; Zhu PW; Wang XD; Byrne CD; Targher G; George J; Zheng MH
    J Clin Transl Hepatol; 2021 Apr; 9(2):194-202. PubMed ID: 34007801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population.
    Govardhan B; Anand VK; Nagaraja Rao P; Balachandran Menon P; Mithun S; Sasikala M; Sowmya TR; Anuradha S; Smita CP; Nageshwar Reddy D; Ravikanth V
    J Clin Exp Hepatol; 2024; 14(4):101371. PubMed ID: 38523737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.